<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383055</url>
  </required_header>
  <id_info>
    <org_study_id>2017LS091</org_study_id>
    <secondary_id>MT2017-29</secondary_id>
    <nct_id>NCT03383055</nct_id>
  </id_info>
  <brief_title>CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig</brief_title>
  <official_title>CMV-MVA Triplex Vaccine to Enhance Adaptive NK Cell Reconstitution After Autologous Hematopoietic Cell Transplantation in Patients With Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, interventional study administering 2 doses of the experimental vaccine&#xD;
      (CMV-MVA Triplex) to 20 evaluable patients (10 CMV-seropositive and 10 seronegative)&#xD;
      undergoing autologous hematopoietic cell transplantation (HCT) for lymphoma or myeloma on&#xD;
      days 28 and 56 post-HCT. The absolute number of adaptive NK cells (CD56dimCD57+NKG2C+) at&#xD;
      various days will be compared.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2018</start_date>
  <completion_date type="Actual">July 10, 2021</completion_date>
  <primary_completion_date type="Actual">July 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the absolute number of CMV-induced adaptive NK cells (CD56dimCD57+NKG2C+) between days 28 and 100 post-auto-HCT in patients with lymphoid malignancies.</measure>
    <time_frame>Day 28 and Day 100</time_frame>
    <description>Change in the absolute number of CMV-induced adaptive NK cells (CD56dimCD57+NKG2C+) on day 28 (pre first vaccine) and day 100 (~1 month after second vaccine) post-auto- HCT in patients with lymphoid malignancies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in absolute Number of CMV-induced adaptive NK Cells</measure>
    <time_frame>Day 28 and Day 100</time_frame>
    <description>Change in absolute number of total NK and NK/T cells between days 28 (first vaccine) and day 100 (~1 month after second vaccine) post-auto-HCT in patients with lymphoid malignancies (lymphoma and myeloma).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to CMV-MVA Triplex vaccine in CMV seropositive vs. seronegative patients</measure>
    <time_frame>Day 28 and Day 100</time_frame>
    <description>Change in the absolute number of adaptive NK cells between day 28 post-transplant and day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>1 Year</time_frame>
    <description>Incidence of progression-free survival at 1 year in patients receiving CMV-MVA Triplex vaccine with historical controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to CMV-MVA Triplex vaccine in lymphoma vs. myeloma patients</measure>
    <time_frame>Day 28 and Day 100</time_frame>
    <description>Change in the absolute number of adaptive NK cells between day 28 post-transplant and day 100.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CMV positive cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CMV negative cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMV-MVA Triplex Vaccine</intervention_name>
    <description>CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT&#xD;
TDap administered on Day 56</description>
    <arm_group_label>CMV negative cohort</arm_group_label>
    <arm_group_label>CMV positive cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Lymphoma or multiple myeloma&#xD;
&#xD;
          -  Planned co-enrollment on current (at the time of this study version) or future&#xD;
             (opening subsequent to this study) standard of care autologous stem cell transplant&#xD;
             protocol.&#xD;
&#xD;
             * Must meet all eligibility requirements of the co-enrolled parent study&#xD;
&#xD;
          -  Sexually active females of childbearing potential and males with partners of&#xD;
             child-bearing potential must agree to use adequate birth control until at least day&#xD;
             100 post-HCT&#xD;
&#xD;
          -  Voluntary written consent signed before performance of any study-related procedure not&#xD;
             part of normal medical care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CMV immunoglobulin, valganciclovir, ganciclovir, foscarnet, or other anti-CMV therapy&#xD;
             within 3 months before the first vaccine is planned. Acyclovir and valacyclovir are&#xD;
             allowed.&#xD;
&#xD;
          -  Pregnant or breast feeding. The FDA has not classified this agent into a specified&#xD;
             pregnancy category. Females of childbearing potential must have a blood test or urine&#xD;
             study within 14 days prior to registration to rule out pregnancy&#xD;
&#xD;
          -  Planned immunotherapy post-HCT. Proteasome inhibitors and/or immunomodulators, such as&#xD;
             but not limited to Lenalidomide or Pomalidomide, used for myeloma maintenance are&#xD;
             allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armin Rashidi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota Hematology, Oncology and Transplantation Department of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 11, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03383055/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

